USPH heads into today's Q2 earnings report carrying the memory of a brutal Q1 print — and positioning that looks more bullish than cautious.
The starkest data point going into the release is the options market. Call dominance is striking, with the put/call ratio at just 0.20 — well below the 20-day average of 0.49 and near the low end of the past year's range. This marks a sharp reversal from late June and early July, when the PCR ran above 7 and hit a 52-week extreme of 9.5. That defensive hedging wave has fully unwound. Options traders are now positioned for upside, not protection. Short interest adds some counterweight: 7.65% of the free float is sold short, and that figure rose 6.5% over the past week — the bears have quietly been adding. Still, borrow costs remain negligible at 0.46%, and availability is ample at roughly 291% of short interest, meaning there is no squeeze pressure in the lending pool that would force shorts to cover.
The bull-bear debate here is largely about whether the Q1 collapse was company-specific or structural. That print was severe — shares fell nearly 20% the next day after the May 7 results, and were still down 11.6% five days later. Bulls point to the acquisition-led growth model, a strong balance sheet, and forward earnings revisions that have been running sharply higher — the 12-month forward EPS growth estimate ranks in the 85th percentile of the market. The consensus targets imply around 20% upside to the current $77.71 close, with Citizens reiterating an Outperform at $98 as recently as June 24. Bears focus on the cost structure: labor expenses in outpatient rehab are compressing margins, patient volumes remain fragile, and the business carries meaningful exposure to managed care reimbursement rates. Barrington Research cut its target from $103 to $90 after the Q1 miss, and JPMorgan trimmed to $100 last November — both maintained positive ratings, but the direction of target revisions has been clearly downward since early 2026.
On the ownership side, one signal stands out. Director Peter Minan bought shares in early June at prices between $61.50 and $63.14 — well below where the stock trades today after a 7% one-month recovery to $77.71. That buying came in the aftermath of the Q1 selloff and represents a modest but genuine vote of confidence from inside the boardroom. Net insider activity over the last 90 days is nominally positive at roughly $150,900, though that reflects the director buys outweighing routine executive sales by the COO and General Counsel.
The Q2 print is ultimately a referendum on whether the Q1 miss reflected a transient shock or a deeper margin problem — and whether the recovery in the stock price since June has gotten ahead of the underlying fundamentals.
See the live data behind this article on ORTEX.
Open USPH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
